[Skip to Content]
[Skip to Content Landing]
Views 181
Citations 0
Comment & Response
July 19, 2018

Regarding the Congruence Between 2 Circulating Tumor DNA Sequencing Assays—Reply

Author Affiliations
  • 1The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland
JAMA Oncol. Published online July 19, 2018. doi:10.1001/jamaoncol.2018.2326

In Reply We thank Oxnard and Paweletz for their comments on our article.1 Kuderer et al2 demonstrated similar discrepancies comparing Guardant360 with tumor tissue, being more frequent at low variant allele fractions (VAFs). However, we disagree that including VAFs “would allow the reader to fully understand the data” because it could only partially explain the discrepancies, and its inclusion would be only mildly informative because it would be necessary to reanalyze the DNA to determine the true nature of these discrepancies with the caveat that other major factors such as timing and processing methods3 would not be considered.

First Page Preview View Large
First page PDF preview
First page PDF preview